Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Sep 20, 2021
AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen
Sep 08, 2021
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction
Aug 25, 2021
AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)
Aug 17, 2021
AIM ImmunoTech Provides Second Quarter 2021 Business Update
Aug 16, 2021
AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.
Jul 09, 2021
AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy
Jul 06, 2021
AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET
Jun 21, 2021
AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen
Jun 14, 2021
AIM ImmunoTech's Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2
May 27, 2021
AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen
8
9
10
11
12
13
14
15
16
17
18
<<
<
>
>>
Privacy